Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

Ajai Chari, MD
Making Bispecific Therapies Work in Community Settings

March 25th 2025

Ajai Chari, MD, stresses the importance of making bispecific therapies more accessible at the community level to improve outcomes in multiple myeloma.

Screenshot of an interview with Ajai Chari, MD
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM

March 21st 2025

Patients with multiple myeloma who did not complete a distress screener were also less likely to receive autologous stem cell transplants. | Image credit: LIghtfieldStudios - stock.adobe.com
Disparities in Multiple Myeloma Distress Screenings May Point to Care Gaps

March 20th 2025

Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com
Rapid IV Isatuximab Could Shift Care Practices in MM

February 13th 2025

cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com
Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

February 7th 2025

Continuing Medical Education
View All
April 3rd 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
April 3rd 2025

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer
April 3rd 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
April 3rd 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

More News

Illustration of T cells | Image credit: Sebastian - stock.adobe.com
October 30th 2023

Study Identifies Mechanisms of Resistance to Immunotherapy for Multiple Myeloma

Rose McNulty
Investigators found that myeloma cells may lose or change targets and subsequently go undetected by these therapies, suggesting that screening for such changes regularly could help guide treatment.
Ixazomib molecule | Image credit: molekuul.be - stock.adobe.com
October 28th 2023

Ixazomib Shows Efficacy, Tolerability in Real-World R/R Multiple Myeloma Treatment

Rose McNulty
A study of patients with relapsed or refractory (R/R) multiple myeloma who received ixazomib-based therapy in real-world settings found the treatment effective and tolerable in clinical practice.
CAR T cell | Image credit: Alpha Tauri 3D - stock.adobe.com
October 27th 2023

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

Courtney Flaherty
Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.
Multiple myeloma cells | Image credit: David A Litman - stock.adobe.com
October 26th 2023

Early Relapse Shows Powerful Prognostic Value in Multiple Myeloma

Rose McNulty
Researchers identified an optimal early relapse time point to incorporate into traditional risk features and formed a novel prognostic classification utilizing both static and dynamic risk.
Multiple myeloma | Image credit: ibreakstock - stock.adobe.com
October 20th 2023

Intensive Therapy More Effective vs Less Intense Therapy in Frail Patients With MM

Rose McNulty
A recent study suggests that more intensive triplet therapy is more effective than less intensive doublet therapy in frail patients with newly diagnosed multiple myeloma (MM), and that more intensive treatment may even improve frailty itself.
Blood Cells | Image credit: Катерина Євтехова - stock.adobe.com.jpg
October 13th 2023

Immunotherapy Sequences May Lead to Disease Resistance/Relapse in Myeloma

Conor Killmurray
BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.
Immune cells attacking cancer | Image credit: Spectral-Design - stock.adobe.com
October 6th 2023

Immune System Traits Linked With Remission in Multiple Myeloma

Rose McNulty
A recent study suggests that a patient’s immune microenvironment plays a key role in the depth and duration of response to multiple myeloma treatment.
Nurse helping man exercise | Image credit: Studio Romantic - stock.adobe.com
September 28th 2023

Physical Activity Improves Performance, Frailty Scores, PROs in Multiple Myeloma

Morgan Bayer
Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores and patient-reported outcomes (PROs) in patients with multiple myeloma receiving systemic treatment.
Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com
September 22nd 2023

Many Factors Influence Selection of CAR T Therapy, Bispecifics in Myeloma

Kyle Doherty
Bispecific antibodies may be more broadly applicable as treatment for patients with multiple myeloma in the short-term, according to Ajai Chari, MD.
Blood cells | Image credit: flashmovie - stock.adobe.com
September 20th 2023

Despite Treatment Improvements, Second Primary Malignancies Adversely Affect MM Prognosis

Rose McNulty
In a real-world study using data from patients diagnosed with multiple myeloma between 2009 and 2021, second primary malignancies adversely impacted survival outcomes in the modern era of therapeutics.
FDA Approved | Image credit: Olivier Le Moal - stock.adobe.com
September 12th 2023

FDA Approves Motixafortide Plus Filgrastim for Stem Cell Mobilization in Multiple Myeloma

Rose McNulty
The combination therapy is the first FDA approved for the mobilization of hematopoietic stem cells prior to autologous transplantation in patients with multiple myeloma.
dr jordan berlin
September 5th 2023

Dr Jordan Berlin Discusses Precision Medicine and Factoring Patient Preferences Into Treatment

Brooke McCormick
Jordan Berlin, MD, FASCO, of Vanderbilt University Medical Center, explained how patient preferences and new treatments are considered, as well as what he is currently working on and his biggest takeaway from The American Journal of Managed Care®’s Institute for Value-Based Medicine® held in Nashville, TN on August 17, 2023.
Dr Joseph Mikhael
August 28th 2023

Dr Joseph Mikhael on Strategies to Increase Diversity in Multiple Myeloma Trials

Skylar Jeremias
Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, highlights several potential strategies to address the historic lack of diversity in multiple myeloma clinical trial populations.
LASZLO - stock.adobe.com
August 26th 2023

Study Suggests CAR T-Cell Therapy Safe, Effective After Allo-SCT in Multiple Myeloma

Rose McNulty
A retrospective analysis of the CARTITUDE-1 trial suggests that patients who have undergone allogeneic stem cell transplant (allo-SCT) prior to receiving chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma experience comparable outcomes to allo-SCT–naïve patients.
Dr Joseph Mikhael: Researchers, Organizations Must Collaborate to Address Disparities in Multiple Myeloma
August 23rd 2023

Dr Joseph Mikhael: Researchers, Organizations Must Collaborate to Address Disparities in Multiple Myeloma

Skylar Jeremias
Researchers and organizations must collaborate to address the persistent disparities in access to treatments for multiple myeloma, explained Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation.
Red FDA approved stamp on white background
August 14th 2023

FDA Approves Elranatamab for Relapsed or Refractory Multiple Myeloma

Kristi Rosa
The FDA has granted accelerated approval to elranatamab-bcmm (Elrexfio) for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received at least 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
FDA approval
August 10th 2023

FDA Grants Talquetamab Accelerated Approval for R/R Multiple Myeloma

Ariana Pelosci
Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.
Calendar
August 4th 2023

Later, Deeper Multiple Myeloma Treatment Responses Linked to Improved Outcomes

Rose McNulty
The study also found that patients with a later best confirmed response to therapy demonstrated improved outcomes compared with patients who experienced an early best confirmed response.
Appointment Reminder to Calendar and Organizer Agenda: © onephoto - stock.adobe.com
July 27th 2023

MM Therapy Attrition Not as High as Previously Reported

Jared Kaltwasser
Fewer patients opt to skip therapy for their multiple myeloma (MM) despite progressive disease than previously thought, a new study suggests.
Case Study Education concept. Analysis of the situation to find a solution: © Funtap - stock.adobe.com
July 25th 2023

Patient Presents With Hyperammonemia After Complete MM Remission in Rare Case

Gianna Melillo
The individual first received their multiple myeloma (MM) diagnosis in 2019.
Doctor holding a sign reading Multiple Myeloma
July 18th 2023

Dr Hans Lee Discusses Infection Mitigation Strategies for MM Treated With CAR T or Bispecific Antibodies

Laura Joszt, MA Skylar Jeremias
Bispecific antibodies or chimeric antigen receptor (CAR) T-cell therapies are both associated with an increased risk of infection for patients with multiple myeloma (MM), explained Hans Lee, MD, of The University of Texas MD Anderson Cancer Center.
stethoscope, red ribbon and colored paper with the word Multiple Myeloma. medical and patient concepts: © Fauzi - stock.adobe.com
July 14th 2023

Need for More Research on Young Patients With Multiple Myeloma

Gianna Melillo
Authors defined any patient 50 years or younger as a “young” patient.
desperate man sitting at hospital bed alone sad and devastated: © Wordley Calvo Stock - stock.adobe.com
July 11th 2023

ERBB2/HER2 Upregulated in MM, Higher Levels Associated With Poor Outcomes

Jared Kaltwasser
The findings suggest existing therapies for other cancers may be helpful in multiple myeloma (MM).
Back pain, kidney inflammation, man suffering from backache at home: © staras - stock.adobe.com
July 8th 2023

Unique Multiple Myeloma Presentation Highlighted in New Case Study

Gianna Melillo
Symptoms initially pointed to toxic alcohol ingestion.
Multiple myeloma. Doctor shows sign/board with wooden frame. Background blue: © MQ-Illustrations - stock.adobe.com
July 6th 2023

Review Details Racial/Ethnic Disparities in MM, Offers Guidance for Improvement

Gianna Melillo
Improving culturally responsive care and practicing cultural humility can help health care providers deliver equitable care for all patients living with multiple myeloma (MM).
Hypophosphatemia measuring. Hypophosphatemia is a low phosphorus level in the blood. 3D render: © JEGAS RA - stock.adobe.com
June 29th 2023

Review Investigates Hypophosphatemia in Multiple Myeloma

Gianna Melillo
There are several reasons patients with multiple myeloma may experience the electrolyte abnormality.
Patients With Penta-Refractory Myeloma May Benefit From BCMA-Directed Therapy
June 22nd 2023

Patients With Penta-Refractory Myeloma May Benefit From BCMA-Directed Therapy

Gianna Melillo
Researchers noted that despite the promising findings, more novel treatments are needed to overcome the disease’s resistance.
Businessman hand checking the interview evaluation paper for job interview at office background, job search, business concept: © mangpor2004 - stock.adobe.com
June 16th 2023

Review Finds EORTC QLQ-MY20 Useful, Robust 25 Years After Development

Gianna Melillo
The treatment landscape for multiple myeloma has shifted since European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was first developed in 1996.
doctor in lab examining blood sample with the text multiple myeloma in screen of computer / technician with blood sample and text multiple myeloma in the software of analysis laboratory: © angellodeco - stock.adobe.com
June 13th 2023

Case Study Suggests Ixazomib Potential Chemotherapy-Free Biological Treatment for Breast Cancer

Gianna Melillo
The 68-year-old patient had multiple myeloma and breast cancer.
image conveying idea of health disparities
June 9th 2023

Even Under Universal Health Care, MM Treatment Access Disparities Persist

Gianna Melillo
Authors concluded more research is needed to understand both patient level and structural barriers to inequitable access to multiple myeloma (MM) care in Canada.
<12345678
...
11>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo